Maravai LifeSciences Holdings, Inc. (MRVI) shareholders
Close on Nov 17, 2026Market cap $1.89BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| GTCR Investment XI LLC Joint filing with GTCR Fund XI/B LP (43.83%), Maravai Life Sciences Holdings, LLC (43.83%) and 5 more | 130,834,085 | 51.81% | 13G (passive) amendment | Sep 30, 2024 |
| 12 West Capital Management LP Joint filing with Joel Ramin (8.20%) | 11,591,335 | 8.20% | 13G (passive) amendment | Dec 31, 2024 |
| BlackRock, Inc. | 8,580,553 | 5.90% | 13G (passive) amendment | Sep 30, 2025 |
| Israel A. Englander Joint filing with Millennium Management LLC (5.20%), Millennium Group Management LLC (5.20%) | 7,773,149 | 5.20% | 13G (passive) | Sep 22, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MRVI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Gtcr LLC | 20,150,005 | 7.76% | $125.74M | – | 3.22% |
| BlackRock, Inc. | 9,970,780 | 3.84% | $62.22M | +625,512 | 0.00% |
| Braidwell LP | 8,702,921 | 3.35% | $54.31M | −1,537,243 | 2.01% |
| First Eagle Investment Management, LLC | 7,342,574 | 2.83% | $45.82M | +4,818,238 | 0.04% |
| 12 West Capital Management LP | 7,060,195 | 2.72% | $44.06M | −200,000 | 8.24% |
| Millennium Management LLC | 6,508,220 | 2.51% | $40.61M | +4,858,730 | 0.01% |
| Vanguard Capital Management LLC | 5,283,665 | 2.03% | $32.97M | −166,037 | 0.00% |
| Ophir Asset Management Pty Ltd | 4,826,698 | 1.86% | $30.12M | New | 2.48% |
| Renaissance Technologies LLC | 4,606,491 | 1.77% | $28.74M | +341,802 | 0.04% |
| Deutsche Bank AG\ | 4,304,927 | 1.66% | $26.86M | +3,446,672 | 0.01% |
| Geode Capital Management, LLC | 3,130,258 | 1.21% | $19.54M | +301,663 | 0.00% |
| State Street Corp | 2,901,706 | 1.12% | $18.11M | +472,989 | 0.00% |
| Nuveen, LLC | 2,857,580 | 1.10% | $17.83M | +2,627,433 | 0.00% |
| JPMorgan Chase & Co | 2,593,559 | 1.00% | $16.57M | +2,236,299 | 0.00% |
| Two Sigma Investments, LP | 2,255,820 | 0.87% | $14.08M | +675,980 | 0.01% |
| Monaco Asset Management SAM | 2,231,026 | 0.86% | $13.92M | −1,189,994 | 1.11% |
| Prudential Financial Inc | 2,152,154 | 0.83% | $13.43M | +2,133,684 | 0.01% |
| Citadel Advisors LLC | 2,122,598 | 0.82% | $13.25M | +638,279 | 0.00% |
| Point72 Asset Management, L.P. | 2,005,579 | 0.77% | $12.51M | −1,199,917 | 0.01% |
| Morgan Stanley | 1,908,276 | 0.73% | $11.91M | −1,411,049 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 178 | 144M | 55.5% | 45 / 57 | 53 / 23 | 44M | 21M |
| Q1 2026 | 158 | 121M | 46.8% | 28 / 51 | 52 / 24 | 17M | 18M |
| Q4 2025 | 159 | 130M | 50.2% | 25 / 45 | 57 / 22 | 18M | 16M |
| Q3 2025 | 160 | 131M | 50.4% | 29 / 47 | 46 / 18 | 12M | 11M |
| Q2 2025 | 150 | 130M | 50.0% | 20 / 56 | 45 / 52 | 14M | 16M |
| Q1 2025 | 184 | 133M | 51.0% | 42 / 61 | 51 / 41 | 27M | 47M |
| Q4 2024 | 185 | 153M | 59.0% | 27 / 66 | 63 / 57 | 28M | 23M |
| Q3 2024 | 217 | 148M | 57.1% | 47 / 66 | 67 / 35 | 32M | 22M |
| Q2 2024 | 206 | 148M | 56.9% | 41 / 72 | 70 / 43 | 28M | 21M |
| Q1 2024 | 210 | 141M | 54.4% | 35 / 75 | 71 / 47 | 20M | 17M |
| Q4 2023 | 223 | 138M | 53.2% | 55 / 81 | 64 / 32 | 32M | 30M |
| Q3 2023 | 205 | 136M | 52.2% | 30 / 97 | 56 / 46 | 30M | 21M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
148 funds held MRVI in Q2 2026, 51% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of MRVI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3,706,103 | 1.43% | $23.13M | 0.00% | Jun 30, 2026 |
| First Eagle Small Cap Opportunity Fund | 3,242,395 | 1.25% | $21.30M | 0.73% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 2,969,903 | 1.14% | $18.53M | 0.02% | Jun 30, 2026 |
| Nuveen Quant Small Cap Equity Fund | 1,596,400 | 0.61% | $10.49M | 0.26% | Jul 31, 2026 |
| Vanguard Extended Market Index Fund | 1,455,424 | 0.56% | $9.08M | 0.01% | Jun 30, 2026 |
| Meridian Contrarian Fund | 1,275,000 | 0.49% | $7.96M | 1.17% | Jun 30, 2026 |
| Fidelity Small Cap Growth Fund | 1,264,380 | 0.49% | $8.31M | 0.09% | Jul 31, 2026 |
| Fidelity Small Cap Index Fund | 1,233,690 | 0.48% | $8.11M | 0.02% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,019,039 | 0.39% | $6.36M | 0.04% | Jun 30, 2026 |
| College Retirement Equities Fund - Total Global Stock Account | 948,570 | 0.37% | $5.92M | 0.00% | Jun 30, 2026 |
| iShares Biotechnology ETF | 741,218 | 0.29% | $4.63M | 0.05% | Jun 30, 2026 |
| Fidelity Small Cap Growth K6 Fund | 659,510 | 0.25% | $4.33M | 0.09% | Jul 31, 2026 |
| Fidelity Extended Market Index Fund | 638,156 | 0.25% | $3.06M | 0.01% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 588,858 | 0.23% | $2.83M | 0.01% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 560,314 | 0.22% | $2.69M | 0.02% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Bernd Brust | Chief Executive Officer, Director | 1,969,520 | 0.76% | Nov 12, 2026 |
| Rajesh Asarpota | Chief Financial Officer | 412,555 | 0.16% | Nov 2, 2026 |
| Kurt Oreshack | General Counsel | 335,767 | 0.13% | Jun 10, 2026 |
| Christine Dolan | See Remarks | 425,318 | 0.16% | May 22, 2026 |
| Peter Michael Leddy | See Remarks | 727,177 | 0.28% | Jul 16, 2025 |
| Kevin Herde | Chief Financial Officer | 674,636 | 0.26% | May 28, 2025 |
| William E. Martin Iii | Chief Executive Officer | 1,814,643 | 0.70% | Mar 19, 2025 |
| Rebecca Buzzeo | See Remarks | 310,933 | 0.12% | Mar 19, 2025 |
| Andrew Burch | See Remarks | 369,183 | 0.14% | Jan 17, 2025 |
| Gregory T. Lucier | Director | 311,200 | 0.12% | Jun 10, 2026 |
| Sean Laurence Cunningham | Director | 184,348 | 0.07% | May 28, 2026 |
| R. Andrew Eckert | Director | 412,183 | 0.16% | May 28, 2026 |
| Luke Joseph Marker | Director | 184,348 | 0.07% | May 28, 2026 |
| Susannah Gray | Director | 216,200 | 0.08% | May 28, 2026 |
| Constantine S. Mihas | Director | 184,348 | 0.07% | May 28, 2026 |
| John A. DeFord | Director | 205,478 | 0.08% | May 28, 2026 |
| Murali Prahalad | Director | 154,607 | 0.06% | Jun 18, 2025 |
| Jessica Hopfield | Director | 199,907 | 0.08% | Jun 18, 2025 |
| Benjamin James Daverman | Director | 138,055 | 0.05% | Jun 18, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Bernd Brust Chief Executive Officer, Director | Nov 9, 2026 | Tax withholding | −29,250 | $7.52 | $219.96K | 1,502,749 |
| Rajesh Asarpota Chief Financial Officer | Oct 30, 2026 | Tax withholding | −5,466 | $8.46 | $46.24K | 286,203 |
| Bernd Brust Chief Executive Officer, Director | Oct 8, 2026 | Tax withholding | −29,250 | $7.43 | $217.33K | 1,531,999 |
| Rajesh Asarpota Chief Financial Officer | Sep 30, 2026 | Tax withholding | −5,465 | $7.65 | $41.81K | 418,021 |
| Bernd Brust Chief Executive Officer, Director | Sep 8, 2026 | Tax withholding | −29,250 | $7.32 | $214.11K | 1,561,249 |
| Rajesh Asarpota Chief Financial Officer | Aug 31, 2026 | Tax withholding | −5,465 | $7.68 | $41.97K | 423,486 |
| Bernd Brust Chief Executive Officer, Director | Aug 10, 2026 | Tax withholding | −29,250 | $6.23 | $182.23K | 1,590,499 |
| Rajesh Asarpota Chief Financial Officer | Jul 30, 2026 | Tax withholding | −5,465 | $6.59 | $36.01K | 428,951 |
| Bernd Brust Chief Executive Officer, Director | Jul 8, 2026 | Tax withholding | −29,250 | $5.92 | $173.16K | 1,619,749 |
| Rajesh Asarpota Chief Financial Officer | Jun 30, 2026 | Tax withholding | −65,584 | $6.39 | $419.08K | 434,416 |
| Kurt Oreshack General Counsel | Jun 10, 2026 | Sale(10b5-1 plan) | −25,000 | $5.10 | $127.50K | 335,767 |
| Gregory T. Lucier Director | Jun 9, 2026 | Gift | −46,293 | – | – | 155,123 |
| Gregory T. Lucier Director | Jun 9, 2026 | Gift | +46,293 | – | – | 156,077 |
| Kurt Oreshack General Counsel | Jun 9, 2026 | Sale(10b5-1 plan) | −25,000 | $5.06 | $126.50K | 360,767 |
| Bernd Brust Chief Executive Officer, Director | Jun 8, 2026 | Tax withholding | −351,001 | $5.02 | $1.76M | 1,648,999 |
| Constantine S. Mihas Director | May 26, 2026 | Award | +46,293 | – | – | 184,348 |
| R. Andrew Eckert Director | May 26, 2026 | Award | +46,293 | – | – | 412,183 |
| Susannah Gray Director | May 26, 2026 | Award | +46,293 | – | – | 216,200 |
| Gregory T. Lucier Director | May 26, 2026 | Award | +46,293 | $4.38 | $202.76K | 201,416 |
| Luke Joseph Marker Director | May 26, 2026 | Award | +46,293 | – | – | 184,348 |
| John A. DeFord Director | May 26, 2026 | Award | +46,293 | – | – | 205,478 |
| Sean Laurence Cunningham Director | May 26, 2026 | Award | +46,293 | – | – | 184,348 |
| Gregory T. Lucier Director | May 26, 2026 | Award | +46,293 | – | – | 201,416 |
| Christine Dolan See Remarks | May 15, 2026 | Award | +5,006 | $1.79 | $8.96K | 425,318 |
| Kurt Oreshack General Counsel | May 15, 2026 | Award | +776 | $2.84 | $2.20K | 385,767 |
| Christine Dolan See Remarks | Mar 16, 2026 | Tax withholding | −28,661 | $3.08 | $88.28K | 420,312 |
| Kurt Oreshack General Counsel | Mar 16, 2026 | Tax withholding | −39,976 | $3.08 | $123.13K | 384,991 |
| Christine Dolan See Remarks | Jan 15, 2026 | Tax withholding | −28,934 | $3.69 | $106.77K | 448,973 |
| Kurt Oreshack General Counsel | Jan 15, 2026 | Tax withholding | −31,902 | $3.69 | $117.72K | 424,967 |
| Gregory T. Lucier Director | Dec 8, 2025 | Buy | +48,528 | $3.67 | $178.10K | 155,123 |
| Gregory T. Lucier Director | Dec 5, 2025 | Buy | +51,472 | $3.70 | $190.45K | 106,595 |
| Christine Dolan See Remarks | Nov 14, 2025 | Award | +4,300 | $1.79 | $7.70K | 477,907 |
| Bernd Brust Chief Executive Officer, Director | Nov 13, 2025 | Buy | +216,212 | $3.25 | $702.69K | 466,771 |
| Bernd Brust Chief Executive Officer, Director | Nov 12, 2025 | Buy | +93,358 | $3.21 | $299.68K | 250,559 |
| Bernd Brust Chief Executive Officer, Director | Nov 11, 2025 | Buy | +157,201 | $3.24 | $509.33K | 157,201 |
| Peter Michael Leddy See Remarks | Jul 15, 2025 | Tax withholding | −5,154 | $2.59 | $13.35K | 727,177 |
| Gregory T. Lucier Director | Jul 10, 2025 | Gift | +89,139 | – | – | 109,784 |
| Gregory T. Lucier Director | Jul 10, 2025 | Gift | −89,139 | – | – | 55,123 |
| Rajesh Asarpota Chief Financial Officer | Jun 30, 2025 | Award | +500,000 | – | – | 500,000 |
| Sean Laurence Cunningham Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 138,055 |
| R. Andrew Eckert Director | Jun 16, 2025 | Award | +231,481 | $2.16 | $500.00K | 365,890 |
| Benjamin James Daverman Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 138,055 |
| Jessica Hopfield Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 199,907 |
| John A. DeFord Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 159,185 |
| Luke Joseph Marker Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 138,055 |
| Gregory T. Lucier Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 144,262 |
| Susannah Gray Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 169,907 |
| Constantine S. Mihas Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 138,055 |
| Murali Prahalad Director | Jun 16, 2025 | Award | +89,139 | $2.16 | $192.54K | 154,607 |
| Bernd Brust Chief Executive Officer, Director | Jun 8, 2025 | Award | +2,000,000 | – | – | 2,000,000 |
| Kevin Herde Chief Financial Officer | May 15, 2025 | Award | +876 | $1.67 | $1.46K | 674,636 |
| Christine Dolan See Remarks | May 15, 2025 | Award | +2,381 | $1.67 | $3.98K | 473,607 |
| Kevin Herde Chief Financial Officer | Mar 17, 2025 | Tax withholding | −8,648 | $2.64 | $22.83K | 279,282 |
| William E. Martin Iii Chief Executive Officer | Mar 17, 2025 | Award | +986,194 | – | – | 1,814,643 |
| Kevin Herde Chief Financial Officer | Mar 17, 2025 | Award | +394,478 | – | – | 673,760 |
| Christine Dolan See Remarks | Mar 17, 2025 | Award | +246,549 | – | – | 471,226 |
| Christine Dolan See Remarks | Mar 17, 2025 | Tax withholding | −5,336 | $2.64 | $14.09K | 224,677 |
| Peter Michael Leddy See Remarks | Mar 17, 2025 | Tax withholding | −5,886 | $2.64 | $15.54K | 337,853 |
| Kurt Oreshack General Counsel | Mar 17, 2025 | Award | +295,858 | – | – | 456,869 |
| Peter Michael Leddy See Remarks | Mar 17, 2025 | Award | +394,478 | – | – | 732,331 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Maravai LifeSciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 104,952 shares on Oct 14, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Kurt Oreshack Officer | Jun 10, 2026 | 25,000 | $127.50K | Jun 10, 2026 | Restricted Stock Vesting |
| Kurt Oreshack Officer | Jun 9, 2026 | 25,000 | $126.50K | Jun 9, 2026 | Restricted Stock Vesting |
| Murali Prahalad Former Director | Dec 23, 2025 | 3,951 | $13.14K | Dec 23, 2025 | Restricted Stock Vesting |
| Jessica Hopfield Former Director | Dec 19, 2025 | 53,951 | $187.53K | Dec 19, 2025 | IPO Shares |
| Kurt Oreshack Officer | Jan 31, 2025 | 25,000 | $125.75K | Jan 31, 2025 | Restricted Stock Vesting |
| Maravai Life Sciences Holdings 2, Llc Owner | May 28, 2024 | 1,531,028 | $16.50M | May 28, 2024 | Pre-IPO reorganization |
| Maravai Life Sciences Holdings 2, Llc Owner | May 28, 2024 | 8,409,946 | $90.66M | May 28, 2024 | Pre-IPO reorganization |
Congress trades
1 trade in Maravai LifeSciences reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Daniel Goldman NY10 | Sold | Apr 10, 2023 | $1K–15K | May 19, 2023 |
See a number that looks wrong?